Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC (TACE-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04268888
Recruitment Status : Recruiting
First Posted : February 13, 2020
Last Update Posted : July 16, 2020
Sponsor:
Information provided by (Responsible Party):
The Clatterbridge Cancer Centre NHS Foundation Trust

Tracking Information
First Submitted Date  ICMJE June 5, 2019
First Posted Date  ICMJE February 13, 2020
Last Update Posted Date July 16, 2020
Actual Study Start Date  ICMJE May 8, 2019
Estimated Primary Completion Date June 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 11, 2020)
  • Overall Survival - phase III primary outcome [ Time Frame: The time until death. Patients discontinuing the study, lost to follow-up or still alive at the end of the study will be censored at the last know date alive, this can be assessed up until 2 years after the last patient. ]
    Measured in days
  • Time to TACE Progression (TTTP) - phase II primary outcome [ Time Frame: The time to confirmatory scan 4 weeks after progression this can be assessed up until 2 years after the last patient is randomised ]
    Measured in days
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 11, 2020)
  • Time to Progression [ Time Frame: Time to date of progression confirmed by RECIST1.1 assessed up until 2 years after the last patient is randomised ]
    Measured in days
  • Radiological response rate [ Time Frame: Through study completion ]
    RECIST 1.1
  • Safety and Toxicity: the number and percentage of patients reporting a Serious Adverse Event (SAE) and Grade 3 or higher Adverse Event (AE) [ Time Frame: Through study completion ]
    the number and percentage of patients reporting a Serious Adverse Event (SAE) and Grade 3 or higher Adverse Event (AE), measured and categorised based on CTCAE (version 4).
  • Progression Free Survival [ Time Frame: Time to progression or death. Assessed up until 2 years. ]
    Measured in days
  • QOL: EORTC QLQ-C30 [ Time Frame: baseline, pre - TACE (first treatment) and 12 weekly thereafter until end of treatment. Assessed up until 2 years after the last patient is randomised ]
    QoL will be scored according to the EORTC QLQ-C30 manual and guidelines.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
Official Title  ICMJE A Two-arm Multi-stage (TAMS) Seamless Phase II/III Randomised Trial of Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
Brief Summary This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.
Detailed Description

A significant proportion of HCC patients present with, or progress to, intermediate stage disease and these patients are typically treated with transarterial chemo-embolisation (TACE) or transarterial embolisation (TAE).

However, since TACE/TAE is generally a palliative therapy, it provides a potential backbone for the addition of effective systemic therapies with the aim of improving survival outcomes. Since TACE may liberate an abundance of tumour antigens and 'danger' signals, it may lend itself to combination with immunotherapeutic strategies.

Nivolumab is a human monoclonal antibody. Nivolumab targets the programmed death-1 PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Patients shall be randomised on a 1:1 basis throughout the study and allocated using pre-generated lists produced by the study statistician. List shall be produced using permuted blocks algorithm with random block sizes of 2 and 4. Stratification factors used in the study are randomising centre, baseline HAP score (A vs. B vs. C) and vascular invasion (No vs. Yes).
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Hepatocellular Carcinoma
Intervention  ICMJE
  • Drug: Nivolumab and TACE/TAE
    Immunotherapy and TACE/TAE
  • Procedure: TACE/TAE
    TACE/TAE (as per local practice)
Study Arms  ICMJE
  • Active Comparator: TACE/TAE Alone
    Transarterial Chemoembolisation (TACE) and/or Transarterial Embolisation (TAE) Alone.
    Intervention: Procedure: TACE/TAE
  • Experimental: TACE/TAE and Nivolumab
    As above for TACE/TAE. Nivolumab adminstered as a flat dose of 480mg IV.
    Interventions:
    • Drug: Nivolumab and TACE/TAE
    • Procedure: TACE/TAE
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 11, 2020)
522
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 2026
Estimated Primary Completion Date June 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Histological diagnosis of HCC and at least one uni-dimensional lesion measurable according to RECIST 1.1 criteria by CT-scan or MRI.
  2. Not a candidate for surgical resection or liver transplantation
  3. Aged ≥16 years and estimated life expectancy >3 months
  4. ECOG performance status 0-1
  5. Adequate haematological function:

    • Hb ≥9g/L
    • Absolute neutrophil count ≥1.0x109/L
    • Platelet count ≥60x109/L
  6. Bilirubin ≤50 μmol/L, AST,ALT and ALP ≤5 x ULN
  7. Adequate renal function; Creatinine ≤ 1.5ULN (Using Cockcroft-Gault Formula)
  8. INR ≤1.6
  9. Child-Pugh A (score ≤6) (Appendix D)
  10. HAP score A, B or C (Appendix E)
  11. No contra-indications to T-cell checkpoint inhibitor therapy (use of immunosuppressive drugs including steroids at dose equivalent to prednisolone >10mg/day unless used as replacement therapy; organ transplantation; subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, lichen planus or other conditions not expected to recur in the absence of an external trigger are permitted to enrol).
  12. Women of child-bearing potential should have a negative pregnancy test prior to study entry. Both men and women must be using an adequate contraception method, which must be continued for 5 months after completion of treatment for women and 7 months for men
  13. Written informed consent

Exclusion Criteria:

  1. Extrahepatic metastasis
  2. Prior embolisation, systemic or radiation therapy for HCC
  3. Any contraindications for hepatic embolisation procedures including portosystemic shunt, hepatofugal blood flow, known severe atheromatosis
  4. Investigational therapy or major surgery within 4 weeks of trial entry
  5. History of variceal bleeding within the past 4 weeks
  6. Child-Pugh cirrhosis B or C (score ≥7)
  7. HAP score D
  8. Hepatic encephalopathy
  9. Ascites refractory to diuretic therapy
  10. Documented occlusion of the hepatic artery or main portal vein5
  11. Hypersensitivity to intravenous contrast agents
  12. Active clinically serious infection > Grade 2 NCI-CTC
  13. Pregnant or lactating women
  14. Known history of HIV infection
  15. HBV chronic infection with HBV DNA > 500IU/mL or without antiviral therapy; HBV patients with cirrhosis should be treated.

17. History of second malignancy except those treated with curative intent more than three years previously without relapse and non-melanotic skin cancer or cervical carcinoma in situ 18. Evidence of severe or uncontrolled systemic disease, or laboratory finding that in the view of the Investigator makes it undesirable for the patient to participate in the trial 19. Psychiatric or other disorder likely to impact on informed consent 20. Patient is unable and/or unwilling to comply with treatment and study instructions 20. Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity

21. Evidence of uncontrolled, active infection, requiring parenteral anti-bacterial, anti-viral or antifungal therapy within 7 days prior to administration of study medication

22. Positive test for latent TB or evidence of active TB

23. Hypersensitivity to any of the active substances or excipients

24. Patients who have received a live vaccine within 30 days prior to the first dose of trial treatment

25. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of the first dose of study drug administration

26. Any uncontrolled inflammatory GI disease including Crohn's Disease and ulcerative colitis

27. Participants with an active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enrol

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 16 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Maria Maguire, PhD 0151 556 maria.maguire2@nhs.net
Contact: David Price 0151 556 david.price9@nhs.net
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04268888
Other Study ID Numbers  ICMJE CA209-9Y9
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party The Clatterbridge Cancer Centre NHS Foundation Trust
Study Sponsor  ICMJE The Clatterbridge Cancer Centre NHS Foundation Trust
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Daniel Palmer, PhD, MD Clatterbridge Cancer Centre
PRS Account The Clatterbridge Cancer Centre NHS Foundation Trust
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP